JACC Publishes ERICA Trial Results Showing Ranexa(R) Reduces Angina Frequency And Nitroglycerin Consumption
Tue, 20 Jun 2006 06:00 AM EST
... CV Therapeutics,Inc. (Nasdaq: CVTX) announced today that the Journal of the AmericanCollege of Cardiology (JACC) has published data from the Efficacy ofRanolazine In Chronic Angina (ERICA) trial. In the ERICA trial, Ranexa(R)(ranolazine extended-release tablets) significantly reduced anginafrequency (p=0.028) and nitoglycerin consumption (p=0. [click link for full article] ...
Related Topics
- Angina
- Angina Pectoris
- Clinical Trials
- Nitroglycerin Spray
- Nitroglycerin Ointment
- Hearing Loss
- Nitroglycerin
- Radiation Therapy
- Nitroglycerin Injection
- Nitroglycerin Buccal ER Tablets
- Pelvic Examination
- Alcohol Consumption
- Nitroglycerin ER
- Desipramine
- Trastuzumab
- Hepatocellular
- Eletriptan
- CK
- Tarceva
- Nitroglycerin Sublingual Tablet

Not Signed In -


